A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Novartis

Status and phase: Withdrawn; Phase 3

Conditions: Chronic Obstructive Pulmonary Disease

Treatments: Drug: QVA149; Drug: fluticasone/salmeterol

Study type: Interventional

Funder types: Industry

Identifiers

NCT01834885

CQVA149A2327

Details and patient eligibility

About

Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >= 40 years, patients with airflow limitation indicated by post-bronchdilation FEV1 >=30% and <80% of predicted normal, current or ex-smokers with a 10 pack year smoking history, patients with a mMRC grade 2 or greater

Exclusion criteria

• prolonged QTCF >450 ms, paroxysmal atrial fibrillation, Type I or uncontrolled Type II diabetes, history of asthma, COPD diagnosis before age 40, receiving treatments not allowed in the study, other concomitant pulmonary diseases.

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups

QVA149

Experimental group

Description:

QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.

Treatment:

Drug: QVA149

fluticasone/salmeterol

Active Comparator group

Description:

Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.

Treatment:

Drug: fluticasone/salmeterol